James Kaye, MD, DrPH
Adjunct Associate Professor
Boston University School of Public Health

MD, Stanford University School of Medicine
DPH/DrPH, Harvard School of Public Health
MPH, Harvard School of Public Health
AB, Harvard College

James Kaye, MD, DrPH, is a medical oncologist/hematologist, epidemiologist, and Senior Director of Epidemiology at RTI-HS. Dr. Kaye completed an internship and residency in internal medicine at the Beth Israel Hospital in Boston and a fellowship in medical oncology/hematology at the Dana Farber Cancer Institute. He then served on the faculty in the Department of Medicine at Harvard Medical School while practicing medical oncology/hematology and coordinating the clinical research program at Harvard Community Health Plan.

In 1991, Dr. Kaye joined the clinical development group at Genetics Institute, Inc. (later Wyeth, now Pfizer) where he directed clinical trials on several hematology/oncology products, two of which were approved for marketing. He participated in numerous Food and Drug Administration interactions, including investigational new drug and biologic license application submissions, advisory committee presentations, and label negotiations.

Dr. Kaye subsequently completed doctoral training in pharmacoepidemiology with a focus on pharmaceuticals and cancer risk. He was senior epidemiologist at the Boston Collaborative Drug Surveillance Program and a faculty member at Boston University School of Public Health, where he continues to serve as adjunct associate professor of epidemiology.

In 2009, Dr. Kaye joined RTI-HS, where he conducts research on postmarketing safety issues (especially cancer risk) and advises RTI-HS staff on a variety of health economics, biostatistics, and other projects relating to hematology/oncology drugs in development. He has chaired or participated in numerous independent data monitoring committees for clinical trials of drugs for the treatment of cancer or hematologic diseases, and he consults with clients on the assessment of cancer-related safety issues for drugs used in other indications. Dr. Kaye has authored more than 100 articles in the peer-reviewed medical literature.

Senior Director, Epidemiology
RTI Health Solutions

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Bhandari NR, Hess LM, Parikh RC, Sireci AN, Krein PM, Kaye JA. Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the United States. Per Med. 2023 Feb 07. PMID: 36749615
  2. Johannes CB, Saltus CW, Kaye JA, Calingaert B, Kaplan S, Gordon MF, Andrews EB. The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database. Pharmacoepidemiol Drug Saf. 2022 Jun; 31(6):643-651. PMID: 35224798; PMCID: PMC9321028; DOI: 10.1002/pds.5422;
  3. Parikh R, Hess LM, Esterberg E, Bhandari NR, Kaye JA. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer. Thyroid Res. 2022 Feb 12; 15(1):2. PMID: 35151352; PMCID: PMC8840546; DOI: 10.1186/s13044-021-00119-9;
  4. Arana A, Pottegård A, Kuiper JG, Booth H, Reutfors J, Calingaert B, Lund LC, Crellin E, Schmitt-Egenolf M, Kaye JA, Gembert K, Rothman KJ, Kieler H, Dedman D, Houben E, Gutiérrez L, Hallas J, Perez-Gutthann S. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021; 13:1141-1153.View Related Profiles. PMID: 35002327; PMCID: PMC8721027; DOI: 10.2147/CLEP.S331287;
  5. Fortuny J, Plana E, Kaye JA. Serum lipid trajectories in the years before a lymphoma diagnosis. Leuk Lymphoma. 2022 02; 63(2):291-303. PMID: 34963420
  6. Boeri M, Purdum AG, Sutphin J, Hauber B, Kaye JA. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. Future Oncol. 2021 Dec; 17(34):4697-4709. PMID: 34581197
  7. Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021 06; 62(6):1325-1334. PMID: 33966583
  8. Goyal RK, Nagar SP, Kabadi SM, Le H, Davis KL, Kaye JA. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population. Cancer Med. 2021 04; 10(8):2690-2702. PMID: 33734606; PMCID: PMC8026937; DOI: 10.1002/cam4.3855;
  9. Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May; 187(1):113-124. PMID: 33428072; PMCID: PMC8062359; DOI: 10.1007/s10549-020-06082-7;
  10. Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer. Breast Cancer Res Treat. 2021 Apr; 186(3):839-850. PMID: 33389410
Showing 10 of 123 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 123 publications over 27 distinct years, with a maximum of 17 publications in 2018


Contact for Mentoring:

RTI Health Solutions, 307 Waverley Oaks Road, Suite 101
Waltham MA 02452-8413
Google Map

Kaye's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department